Your browser doesn't support javascript.
loading
Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial.
Hassanzadeh, Hamid; Baber, James; Begier, Elizabeth; Noriega, David C; Konishi, Hiroaki; Yato, Yoshiyuki; Wang, Michael Y; Le Huec, Jean Charles; Patel, Vikas; Varga, Peter; Liljenqvist, Ulf; Conly, John; Sabharwal, Charu; Munjal, Iona; Cooper, David; Radley, David; Jaques, Anna; Patton, Michael; Gruber, William C; Jansen, Kathrin U; Anderson, Annaliesa S; Gurtman, Alejandra.
Afiliación
  • Hassanzadeh H; Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA.
  • Baber J; Pfizer Inc, Vaccine Clinical Research, Sydney, New South Wales, Australia.
  • Begier E; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Noriega DC; Department of Orthopaedics, Hospital Universitario de Valladolid, Valladolid, Spain.
  • Konishi H; Department of Orthopaedic Surgery, Nagasaki Rosai Hospital, Nagasaki, Japan.
  • Yato Y; National Hospital Organization Murayama Medical Center, Orthopedics and Sports Medicine Neurosciences & Neurology Surgery, Tokyo, Japan.
  • Wang MY; Neurological Surgery, University of Miami, Miami, Florida, USA.
  • Le Huec JC; Department of Orthopaedic and Traumatology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux University, Bordeaux, France.
  • Patel V; Department of Orthopaedic Surgery, University of Colorado School of Medicine, Denver, Colorado, USA.
  • Varga P; National Center for Spinal Disorders, Buda Health Center, Spine Center, Budapest, Hungary.
  • Liljenqvist U; Department of Orthopaedic Surgery, St. Franziskus-Hospital Munster Orthopaedie II, Muenster, Germany.
  • Conly J; Department of Medicine, Foothills Medical Centre, Alberta Health Services and University of Calgary, Calgary, Alberta, Canada.
  • Sabharwal C; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Munjal I; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Cooper D; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Radley D; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Jaques A; Pfizer Inc, Vaccine Clinical Research, Sydney, New South Wales, Australia.
  • Patton M; Pfizer Ltd, Vaccine Clinical Research, Hurley, United Kingdom.
  • Gruber WC; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Jansen KU; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Anderson AS; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
  • Gurtman A; Pfizer Inc, Vaccine Research, Pearl River, New York, USA.
Clin Infect Dis ; 77(2): 312-320, 2023 07 26.
Article en En | MEDLINE | ID: mdl-37125490
ABSTRACT

BACKGROUND:

Staphylococcus aureus is a global pathogen that is frequently responsible for healthcare-associated infections, including surgical site infections (SSIs). Current infection prevention and control approaches may be limited, with S. aureus antibiotic resistance remaining problematic. Thus, a vaccine to prevent or reduce S. aureus infection is critically needed. We evaluated the efficacy and safety of an investigational 4-antigen S. aureus vaccine (SA4Ag) in adults undergoing elective open posterior spinal fusion procedures with multilevel instrumentation.

METHODS:

In this multicenter, site-level, randomized, double-blind trial, patients aged 18-85 years received a single dose of SA4Ag or placebo 10-60 days before surgery. SA4Ag efficacy in preventing postoperative S. aureus bloodstream infection and/or deep incisional or organ/space SSIs was the primary end point. Safety evaluations included local reactions, systemic events, and adverse events (AEs). Immunogenicity and colonization were assessed.

RESULTS:

Study enrollment was halted when a prespecified interim efficacy analysis met predefined futility criteria. SA4Ag showed no efficacy (0.0%) in preventing postoperative S. aureus infection (14 cases in each group through postoperative day 90), despite inducing robust functional immune responses to each antigen compared with placebo. Colonization rates across groups were similar through postoperative day 180. Local reactions and systemic events were mostly mild or moderate in severity, with AEs reported at similar frequencies across groups.

CONCLUSIONS:

In patients undergoing elective spinal fusion surgical procedures, SA4Ag was safe and well tolerated but, despite eliciting substantial antibody responses that blocked key S. aureus virulence mechanisms, was not efficacious in preventing S. aureus infection. Clinical Trials Registration. NCT02388165.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Staphylococcus aureus Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones Estafilocócicas / Staphylococcus aureus Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos